Brain-Computer Interface Industry "Accelerates" as Listed Companies Rush to Seize Opportunities

Securities Daily Reporter Xu Linyan

“Brain-computer interfaces” were included in this year’s government work report for the first time, explicitly identified as one of the future industries to be cultivated and developed.

Recently, relevant policies from the national to local levels continue to be released favorably, steadily increasing attention to the brain-computer interface industry. Listed companies are rushing to deploy in this sector, continuously promoting the industry’s acceleration from laboratory research to practical applications.

Policy-Driven Catalysis

Multiple regions have issued favorable policies, increasing investment in the brain-computer interface industry and driving the sector’s continued growth.

On March 10, the Jiangsu Provincial Department of Industry and Information Technology and eight other departments issued the “Jiangsu Province Brain-Computer Interface Industry Innovation Development Action Plan.” It mentions building medical and health application scenarios, promoting the construction of clinical trial sites for brain-computer interfaces in top-tier hospitals within the province, encouraging clinical research related to brain-computer interface implants, supporting qualified entities to carry out relevant clinical diagnosis and treatment services, and aiming to have no less than 20 brain-computer interface products approved through medical device registration by 2030.

On the same day, the General Office of the Guangdong Provincial Government issued the “Guangdong Province Accelerating the Cultivation and Development of New Tracks to Lead the Modern Industrial System Construction (2026–2035).” It proposes focusing on key areas such as implantable electrodes, cerebrovascular interventional electrodes, high-channel, high-speed data acquisition chips, high-performance, low-power processing chips, and specialized software tools for brain signal encoding and control interaction. The plan aims to accelerate the launch of innovative products in sensing evaluation, emotion detection, control interaction, and neural regulation, both implantable and non-implantable.

The continuous release of favorable policies is expanding the application scenarios for brain-computer interfaces. According to research reports from China Merchants Securities, there are currently no fewer than 30 application scenarios, with healthcare, consumer applications, and safety production being hotspots. The ongoing deepening and diversification of these scenarios will be the core driver of long-term industry growth.

“China’s brain-computer interface industry is at a critical leap from laboratory to application scenarios,” said Zheng Lei, Chief Economist at Samoyed Cloud Technology Group, to Securities Daily. According to Precedence Research data, from 2022 to 2024, the revenue share of non-invasive brain-computer interfaces accounts for over 80% of the market. The next three to five years are expected to be a period of rapid industrialization and application of non-invasive brain-computer interface technology, as well as a breakthrough phase for invasive brain-computer interface development.

“Non-invasive brain-computer interfaces have advantages in consumer markets due to their lower risk and broader practicality. Currently, non-invasive products are gradually entering the market, such as some smart wearable devices. Invasive brain-computer products face higher technical and ethical risks and are mostly in clinical trials or small-scale applications,” said Yu Fenghui, Senior Researcher at Pangu Think Tank, to Securities Daily.

Listed Companies Seize the Opportunity

The development prospects of the brain-computer interface industry are broad, and listed companies are actively deploying to seize the golden opportunity for industry growth.

Beijing Chengyi Tong Control Technology Group Co., Ltd. (hereinafter “Chengyi Tong”) is gaining a competitive edge through differentiated deployment. “The company’s controlling subsidiary, Beijing BrainLink Technology Co., Ltd., continuously iterates its proprietary hardware and software technologies for EEG collection, gradually building a core-competitiveness-based brain-computer interface platform model, laying a solid foundation for scalable business expansion,” a company representative told Securities Daily.

In terms of development approach, Chengyi Tong has taken a distinctive path of deep integration of “technology + clinical + industry-university-research”: on one hand, focusing on technological innovation, staying at the forefront of the industry, continuously enhancing the technological advancement and stability, and leveraging AI to optimize data processing and applications; on the other hand, collaborating with top domestic hospitals to conduct clinical research, promoting the transformation of technology into treatments for neurological and psychiatric diseases, forming a differentiated closed loop of “research and development—validation—transformation.”

On March 10, Kefu Medical Technology Co., Ltd. stated on an interactive platform that the company is currently mainly deploying in the brain-computer interface field through strategic investments. The related layout is still in the early stages and is not expected to significantly impact the company’s short-term performance.

On March 9, Jiangsu Aipeng Medical Technology Co., Ltd. indicated that in terms of commercialization, they believe non-invasive brain-computer interfaces will be faster to land and scale compared to invasive ones. Their layout in brain-computer interfaces considers the company’s existing technology and channels, prioritizing the commercialization of non-invasive products, while also strategically increasing high-barrier invasive technology deployment through external expansion.

The number of entrants into the brain-computer interface industry continues to grow. “Companies should choose differentiated paths based on their resource endowments: those with advantages in medical channels can focus on clinical needs, consumer electronics companies can develop non-invasive inclusive applications, and firms with strong technological capabilities can tackle core components,” Zheng Lei said. However, companies also need to face challenges such as the lack of industry standards, long clinical validation cycles, and stricter ethical regulations, balancing technological innovation with business sustainability.